Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
Xconomy
SEPTEMBER 6, 2019
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.
Let's personalize your content